We report a case of peripheral neuropathy following highly active antiretroviral therapy (HAART) initiation in a patient coinfected with HIV and Mycobacterium leprae and review the literature on leprosy-associated immune reconstitution inflammatory syndrome (IRIS). Physicians in charge of HIV-infected patients originating from countries endemic for leprosy should be aware of this risk of leprosy-associated IRIS when starting HAART.
Introduction
Leprosy remains a common disease in developing countries. HIV prevalence is also high in many of these countries where leprosy is endemic. 1, 2 It was initially predicted that coinfection with HIV and Mycobacterium leprae would emerge as a public health issue. However, up to now, the HIV epidemic seemed to have had little impact on both the epidemiology and the natural course of leprosy. 3 However, the recent availability of highly active antiretroviral therapy (HAART) has led to the emergence of new leprosy cases because of HAART-induced immune reconstitution. Leprosy is now considered a new unmasked infectious disease associated with the immune reconstitution inflammatory syndrome (IRIS). 4, 5 We report here a new case of an HIV-infected patient who developed a relapse of leprosy with neurological clinical presentation 10 months after HAART initiation and review previously reported cases.
Case Report
A 43-year-old man, originating from Haiti, had a 5-month history of progressive glove and stocking distribution sensory deficit without motor neuropathy. He was diagnosed with HIV infection in December 2004 when he presented with oral candidiasis. At that time, the patient had a CD4 count of 25 cells/mm 3 and a plasma HIV RNA level of more than 100 000 copies/mL. HAART was started in April 2005 with tenofovir (TDF), lamivudine (3TC), and efavirenz (EFV). After 10 months, at the time of onset of neurological symptoms, the viral load was undetectable and the CD4 count was at 110 cells/mm 3 . Electromyography (EMG) revealed severe, diffuse, and sensitive polyneuropathy with demyelinizing and axonal damages. The cerebrospinal fluid (CSF) was acellular, with a protein level of 1.66 g/L and a normal glucose level. CSF cultures remained negative. Because reverse transcriptase inhibitors were initially suspected of being responsible for the neuropathy, they were stopped and EFV was switched to lopinavir/ ritonavir (LPV/r). The patient also received intravenous (IV) immunoglobulins for presumptive Guillain Barré syndrome. Despite these treatments, his neurological symptoms worsened in both hands and feet with the emergence of fingers ulcerations due to burns ( Figure 1 ). Leprosy was then suspected and on careful examination thickened ulnar and posterior tibial nerves were found as well as a few ill-defined hypopigmented skin lesions on the trunk. The patient then remembered that he had been treated for leprosy in Haiti in 1990 for 3 years. The diagnosis of leprosy-induced neuropathy was confirmed by positive earlobes and slit-skin smears examination for M leprae (2þ: 1 to 10 Hansen bacilli/10 fields). According to the World Health Organization (WHO) bacteriological classification, the patient was classified as multibacillary leprosy (the presence of bacilli whatever their number). He then received the WHO-recommended multidrug therapy (MDT) including rifampin (600 mg/d), dapsone (100 mg/d), and clofazimine (100 mg/d) with the addition of prednisone (0.5 mg/kg per d) to improve acute neurologic symptoms. To avoid drug interactions between rifampin and HAART, antiretroviral therapy (ART) was switched again to TDF, emtricitabine (FTC) , and EFV. The skin lesions disappeared within a few weeks while the sensory deficit slowly improved. There was a marked improvement of the fingers' ulcerations after 3 months. Steroids were gradually tapered and stopped after 1 year of treatment. After 2 years of MDT, slit smears were negative, MDT was stopped, and the neuropathy slowly improved.
Discussion
Leprosy remains an important public health problem in at least 15 countries in the world including Brazil, India, Nepal, Haiti, and a number of African countries. 1 Leprosy has a large spectrum of clinical manifestations, which are determined in part by the host's immunologic response. Leprosy affects mainly the skin and the peripheral nerves. Skin lesions are the usual revealing clinical features and the diagnosis is usually made by a skin biopsy. In some cases, however, leprosy may be revealed by isolated neurological symptoms. This form, known as pure neural leprosy, affects 5% to 18% of the newly detected cases. 1 In these cases, the diagnosis, often difficult, is established by earlobes slit smears examination and/or nerve biopsies.
In 1966, Ridley and Jopling proposed a classification of leprosy in 5 forms. 6 At one pole, patients with polar tuberculoid leprosy have a strong anti-M leprae cell-mediated immune response and no detectable bacilli. At the other pole, patients with polar lepromatous leprosy are characterized by the lack of specific immune response and a high bacillary load. During the course of leprosy, spontaneously or following treatment, patients may develop acute inflammatory reactional leprosy states, such as erythema nodosum leprosum and reversal reaction. 7 Reversal reactions are associated with an enhancement of anti-M leprae cellular immune responses with a shift from the lepromatous pole to the tuberculoid pole in borderline patients. These reversal reactions with severe neuritis seem to be more frequent among the patients coinfected with HIV, even before the introduction of HAART. 8 A number of leprosy-associated IRIS cases that resemble type 1 reversal reactions have also been reported following HAART initiation (Table 1 ). Most cases have been reported in Brazil and India, and a few cases in Haiti, and all occurred a median of 2 months after the initiation of HAART. The median age was 37 years, and male/female sex ratio was 24/8. Median CD4 count at the time of HAART initiation was 98 cells/mm 3 , and at the time of reversal reaction it increased to 229 cells/mm 3 . Clinical symptoms included the reappearance or exacerbation of the previous cutaneous lesions and the occurrence of acute painful neuritis. Most of the cases were treated as non-HIV-infected leprosy patients and well responded to the classical WHOrecommended MDT and some cases received corticosteroids for acute neuritis.
As peripheral neuropathy is common among HIV-infected patients and can be due to multiple causes (drug-associated neurotoxicity, cytomegalovirus (CMV) infection, or HIV infection), the diagnosis of leprosy can be overlooked. Isolated neuropathy developing under HAART in a patient originating from a country endemic for leprosy should therefore suggest the diagnosis of leprosy-associated IRIS and prompt a search for M leprae in earlobes slit smears or nervous biopsies.
Interestingly, our patient had already been treated for leprosy and received the multibacillary WHO-recommended MDT for 3 years. The presence of M leprae in his slit smears suggests that he had a leprosy relapse that was silent until HAART was initiated. As the relapse rate of leprosy after multibacillary MDT ranges from 0.3% to 20%, other cases such as ours are likely to be reported. 23 In conclusion, HIV-infected patients coming from leprosy-endemic countries with dermatological and/or neurological symptoms should be investigated for leprosy, especially when these clinical symptoms occur after the initiation of HAART.
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